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Background: It had been reported that BPA significantly improved pulmonary artery hypertension, New York Heart Association (NYHA) 
class and 6-minute walk distances (6MWD), in patients whose mean pulmonary arterial pressure (mPAP) >30mmHg. However, CTEPH 
patients with mPAP≤30mmHg still have the symptom such as dyspnea on effort, and the decreased exercised capacity. Therefore, this 
study investigate the efficacy of BPA for patients with mPAP≤30 mmHg.
methods: Between April 2012 and June 2014, a total of 65 CTEPH patients were treated with BPA. The 41 of 65 patients were performed 
follow-up study because the other 24 patients were not performed until final session. 41 patients were divided into 2 groups; 33 patients 
with baseline mPAP>30mmHg and 8 patients with baseline mPAP≤30mmHg. We evaluated NYHA, 6MWD, Peak VO2, and hemodynamic 
status both before and after BPA.
results: Total BPA sessions were average 2.0±0.5 sessions for patients with baseline mPAP≤30mmHg and 4.2±1.4 sessions for patients 
with baseline mPAP>30mmHg. The evaluation after BPA was performed 6.5±4.1 months after BPA final session. NYHA improved from 
2.5±0.5 to 1.8±0.5 (p<0.05) in mPAP≤30mmHg group, and 3.0±0.5 to 1.9±0.4 in mPAP>30mmHg group. 6MWD improved from 433±98 
to 516±128 meters (P<0.01) in mPAP≤30mmHg group, and from 296±161 to 481±85 meters in mPAP>30mmHg group. mPAP decreased 
from 26.9±1.9 to 20.4± 2.1mmHg (p<0.01) in mPAP≤30mmHg group, and from 44.0±8 to 28.0± 7 mmHg in mPAP>30mmHg group. and 
PVR decreased from 5.1±1.3 to 3.7±0.5 wood unit(p<0.01) in mPAP≤30mmHg group, and from 13±5 to 7±2 wood unit in mPAP>30mmHg 
group. PeakVO2 increased from 17.3 ± 3.5 to 20.9±3.9 ml/min/kg (p<0.001) in mPAP≤30mmHg group, and from 14.6 ± 3.3 to 18.3±3.4 
ml/min/kg (p<0.001)in mPAP>30mmHg group.Delta NYHA, PVR, mPAP improvements were significantly better in mPAP>30mmHg group 
than mPAP≤30mmHg group, however, delta 6MWD and Peak VO2 were similar in both group. There were no severe complication such as 
mechanical ventilation and death.
conclusion:  For CTEPH patients with mPAP ≤30mmHg, since BPA improved exercise capacity not inferior to mPAP >30mmHg group and 
hemodynamic status without adverse event, it should be a therapeutic option.
